HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Ulta Ups FY 2022 Sales Projections; US House Targeting PFAS Research; Personal Care News In Brief

Executive Summary

Ulta Beauty doubles its comparable sales growth projections for fiscal 2022 to between 6% and 8%, citing faster-than-expected makeup recovery. German company Henkel is recalling Alterna Bond Repair Leave-in Heat Protection Spray due to potential microbial contamination. More news in brief.

You may also be interested in...



Industry Pushes For Revised PFAS Definition In California Bill Seeking Cosmetic Ban

The Personal Care Products Council and other industry groups suggest they will support AB 2771 if amendments are made to promote international harmonization, among other changes. Already they advocated successfully for the bill’s scope to be limited to intentionally added PFAS, not “the mere presence of trace levels of fluorine in the product.”

EU Business News: Biofarm Wants Double-Digit Growth, Medis Strikes Salix Deal, Theramex Gets New Owners

A round-up of the latest European consumer health business news: Romania's Biofarm targets double-digit growth in 2022; Slovenia's Medis strikes deal with Salix for new product launch; and the UK's Theramex acquired by Carlyle and PAI Partners.

Ulta Beauty Achieves 38% Sales Growth In 2021, Predicts 'Normalized' 2022

Ulta’s shop-in-shop partnership with Target Corporation, expansion of its Conscious Beauty platform, and its growing investment in BIPOC-associated brands were among highlights in fiscal 2021, which benefited from comparisons against 2020 when the world locked down under siege by COVID-19.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

RS152577

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel